Most Frequent Side Effects of Polivy
Polivy (polatuzumab vedotin-piiq), used with bendamustine and rituximab for relapsed or refractory diffuse large B-cell lymphoma, causes side effects in most patients. In clinical trials like GO29365, 95% of patients experienced at least one adverse reaction.[1][2]
Common effects (occurring in ≥20% of patients) include:
- Neutropenia (41%)
- Thrombocytopenia (39%)
- Anemia (36%)
- Peripheral neuropathy (39%)
- Fatigue (37%)
- Diarrhea (31%)
- Pyrexia (26%)
- Decreased appetite (24%)
- Pneumonia (21%)
These rates come from 139 patients in the pivotal trial; higher doses or combinations increase incidence.[1]
How Polivy's Side Effects Compare to Rituximab-Bendamustine Alone
The triplet regimen with Polivy raises severe (Grade 3-4) side effect rates compared to BR alone:
- Neutropenia: 41% vs 31%
- Thrombocytopenia: 39% vs 25%
- Anemia: 36% vs 20%
BR alone had a 74% adverse event rate, but Polivy addition pushes it to 95%, with 46% discontinuing due to toxicity.[1][2] Peripheral neuropathy, unique to Polivy, affects 39% (14% Grade 3-4) and led to 9% discontinuations.
Serious Side Effects and What Patients Report
Grade 3-4 events hit 90% of patients, including infections (28%, like pneumonia) and infusion reactions (17%).[1] Post-marketing, myelosuppression and neuropathy persist; patient forums note neuropathy as long-lasting, sometimes months after treatment.[3]
Fatalities occurred in 6% from infections or disease progression.[2]
Why Some Side Effects Are More Common in Real-World Use
Trials underreport long-term neuropathy (up to 40% ongoing at 1 year) and infections due to controlled settings. Elderly patients (>65 years, 43% of trial) face higher risks: 52% severe neutropenia vs 33% under 65.[1] Pre-existing neuropathy worsens outcomes.
Managing and Monitoring Polivy Side Effects
Dose delays (58%) or reductions (27%) are common for neuropathy or cytopenias. Prophylaxis with G-CSF reduces neutropenia risk. Patients should report numbness or fever immediately; neuropathy may improve but rarely resolves fully.[1][4]
Sources:
[1]: Polivy Prescribing Information (Genentech, 2023)
[2]: GO29365 Trial Data (FDA Approval Summary)
[3]: Drugs.com Polivy Reviews
[4]: NCCN Guidelines for B-Cell Lymphomas (2024)